Study wrapper · #1020
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
Nejat C, Lin R, Addo D, et al. Clinical case reports. 2026.
DOI: 10.1002/ccr3.73183PubMed: 42487660
Editor's note
A single case report describing tirzepatide-specific hypersensitivity in a 25-year-old woman who later tolerated semaglutide after supervised testing. As an individual case, it cannot establish how common such reactions are, but it illustrates that hypersensitivity to one GLP-1-based agent does not necessarily extend to others in the class. The main value is in documenting a diagnostic approach using intradermal testing and supervised challenge.
Plain-language abstract
A single patient developed an allergic reaction (lip swelling and hives) after a higher dose of tirzepatide but tolerated semaglutide without problems. Skin testing confirmed the reaction was specific to tirzepatide.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Mixed
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillarsn=——2026